Myosin motor domains carrying mutations implicated in early or late onset Hypertrophic Cardiomyopathy have similar properties
C. D. Vera, C. A. Johnson, J. Walklate, A. Adhikari, M. Svicevic, S. Mijailovich, A. Combs, S. J. Langer, K. M. Ruppel, J. A. Spudich, M. A. Geeves, L. A. LEINWAND
Abstract
Hypertrophic Cardiomyopathy (HCM) is a common genetic disorder that typically involves left ventricular hypertrophy and cardiac hypercontractility. Mutations in {beta} cardiac myosin heavy chain ({beta}-MyHC) are a major cause of HCM, but the specific mechanistic changes to myosin function that lead to the disease remain incompletely understood. Predicting the severity of any single {beta}-MyHC mutation is hindered by a lack of detailed evaluation at the molecular level. In addition, since the cardiomyopathy can take 20 or more years to develop, the severity of the mutations must be somewhat subtle. We hypothesized that mutations which result in early onset disease may show more severe molecular changes in function compared to later onset mutations. In this work, we performed steady-state and transient kinetic analyses of myosins carrying 1 of 7 missense mutations in the motor domain. Of these 7, 4 have been identified in early onset cardiomyopathy screens. The derived parameters were used to model the ATP driven cross-bridge cycle. Contrary to our hypothesis, the results show no clear differences between early and late onset HCM mutations. Despite the lack of distinction between early and late onset HCM, the predicted occupancy of the force-holding actin.myosin.ADP complex at [Actin] = 3 Kapp along with the closely related Duty Ratio (DR; fraction of myosin in strongly attached force-holding states) and the measured ATPases all change in parallel (in both sign and degree of change) compared to wild type (WT) values. Six of the 7 HCM mutations are clearly distinct from a set of DCM mutations previously characterized.
02 /Specification & Classification
Click any tag to browse matching papers- Organism
- Assay
- Research Focus
- Approach
Reproducibility ledger
Nobody has reported trying to reproduce this paper yet. Did you replicate an experiment or run the code? Your report saves the next lab a week.
Sign in to file a reproducibility report.
Related papers
- Mutations in the catalytic domain of human β-cardiac myosin that cause early onset hypertrophic cardiomyopathy significantly increase the fundamental parameters that determine ensemble force and velocity
Arjun S Adhikari, Kristina B Kooiker, … Kathleen M Ruppel·bioRxiv·Aug 9, 2016
- Hypertrophic cardiomyopathy disease results from disparate impairments of cardiac myosin function and auto-inhibition
J. Robert-Paganin, D. Auguin, A. Houdusse·bioRxiv·May 17, 2018
- Hypertrophic cardiomyopathy mutations at the folded-back sequestered β-cardiac myosin S1-S2 and S1-S1 interfaces release sequestered heads and increase myosin enzymatic activity
A. S. Adhikari, D. V. Trivedi, … K. M. Ruppel·bioRxiv·Jan 31, 2019
- Hypertrophic cardiomyopathy mutations in the pliant and light chain-binding regions of the lever arm of human β-cardiac myosin have divergent effects on myosin function
M. Morck, D. Bhowmik, … K. M. Ruppel·bioRxiv·Oct 11, 2021
- A myosin hypertrophic cardiomyopathy mutation disrupts the super-relaxed state and boosts contractility by enhanced actin attachment
Robert C. Cail, Bipasha Barua, … E. Michael Ostap·Proceedings of the National Academy of SciencesPeer-reviewed·Dec 24, 2025
- Single-molecule analysis sheds light on cardiac myosin dysfunction due to hypertrophic cardiomyopathy mutation A57D in ventricular myosin light chain-1 (MLC1v)
Tianbang Wang, Emrulla Spahiu, … Mamta Amrute‐Nayak·bioRxiv·Mar 9, 2026